Press Releases

Life Technologies to Present at UBS Global Life Sciences Conference

CARLSBAD, Calif.--(BUSINESS WIRE)--Sep. 15, 2009-- Life Technologies Corporation (NASDAQ: LIFE) today announced it will present at the UBS Global Life Sciences Conference on September 22 at 8:30 a.m. Eastern Time at the Grand Hyatt Hotel in New York City. Greg Lucier, Life Technologies’ Chairman and Chief Executive Officer, will be presenting on behalf of the company. A live webcast of the presentation will be available on the investor relations page of the company’s website at ir.lifetechnologies.com. A replay of the webcast will be available for three weeks following the conference.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.

Source: Life Technologies Corporation

Life Technologies CorporationAmanda ClardyVice President, Investor Relations760-476-7075ir@lifetech.com

News

  • TGen Study

    LifeTechnologies Corporation announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies. The goal of this first-of-its-kind research collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals.

    Read All Close
  • SMS Technology

    Life Technologies Corporation announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

    Read All Close
  • SOLiD PI ANNOUNCED

    Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD(TM) PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

    Read All Close

Life (Common Stock)